SEC Filing Summary: Aeglea BioTherapeutics, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K reports on the 2017 Annual Meeting of Stockholders held by Aeglea BioTherapeutics, Inc. on June 7, 2017. The filing details the outcomes of three specific proposals submitted to security holders. Note: The input metadata references "Spyre Therapeutics, Inc.", but the filing text explicitly identifies the registrant as "Aeglea BioTherapeutics, Inc."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
The following proposals were adopted at the Annual Meeting:
- Election of Directors: Three Class I directors were elected to three-year terms expiring at the 2020 Annual Meeting:
- Sandesh Mahatme: 8,102,169 shares For; 768,417 shares Withheld.
- George Georgiou: 8,239,487 shares For; 631,099 shares Withheld.
- Suzanne Bruhn: 8,865,161 shares For; 5,425 shares Withheld.
- Ratification of Auditors: PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2017.
- Votes: 10,160,918 For; 4,426 Against; 1,000 Abstaining.
- Equity Incentive Plan Approval: Shareholders re-approved the Internal Revenue Code Section 162(m) limits of the 2016 Equity Incentive Plan to preserve corporate income tax deductions.
- Votes: 6,603,476 For; 2,263,869 Against; 3,241 Abstaining.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the voting results.
Key Facts for Investor Verification
- Verify the correct registrant name is Aeglea BioTherapeutics, Inc., not Spyre Therapeutics, Inc.
- Confirm the successful election of the three new Class I directors and their term expiration in 2020.
- Note the significant number of shares voted against the Section 162(m) limits of the Equity Incentive Plan (2,263,869 shares).
- Confirm the appointment of PricewaterhouseCoopers LLP as the auditor for the 2017 fiscal year.